Synergy Pharmaceuticals Appoints Gail M. Comer, M.D. as Chief Medical Officer
3 days 12 hours 1 minutes ago - GlobeNewswire via Comtex
Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) (Nasdaq:SGYPU) (Nasdaq:SGYPW), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the appointment of Gail M. Comer, M. D. as Chief Medical Officer, effective May 14, 2012. In this newly created position, Dr. Comer will report directly to President and Chief Executive Officer, Gary S. Jacob, Ph.D., and will be responsible for guiding Synergy's clinical programs, including the ongoing Phase II/III study of plecanatide, the Company's leading drug candidate.
"Dr. Comer is a tremendous addition to our management team, and I am very pleased to welcome her to Synergy," said Dr. Jacob. "Dr. Comer has an extremely strong medical and academic background, along with extensive industry experience in clinical research."
Dr. Comer, a board-certified gastroenterologist and hepatologist, has more than 14 years of experience in the pharmaceutical industry, having spent 7 years at Abbott Laboratories as a Medical Director, six years in clinical development at Wyeth Research as Senior Medical Director, and most recently as Senior Director of the BioTherapeutics Research Unit at Pfizer. While at Wyeth, Dr. Comer was Medical Research Leader in Gastroenterology, and more recently, while at Pfizer, was Clinical Lead for multiple biologic compounds in early development in inflammatory bowel disease. Dr. Comer was an Associate Professor of Clinical Medicine at The State University of New York at Stony Brook prior to joining the pharmaceutical industry.
"Synergy's GC-C receptor agonist program represents an innovative and exciting technology platform that I believe offers great potential for the treatment of patients with GI disorders and diseases," said Dr. Comer. "I believe the depth of my experience in clinical development specifically in gastroenterology will play a pivotal role in maximizing Synergy's clinical potential with these drugs, and am very pleased and excited to be joining Synergy at this opportune time."